David B MacLean

Title: David B MacLean: Innovator in Prostate Cancer Treatment

Introduction

David B MacLean is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of prostate cancer. With a total of 6 patents to his name, MacLean's work is recognized for its innovative approaches to cancer therapy.

Latest Patents

MacLean's latest patents focus on methods for treating prostate cancer, including advanced stages of the disease. One of his key inventions involves administering a daily dose of at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt. Another method includes an oral load dose formulation ranging from 240 mg to 480 mg, followed by a maintenance dose of 80 mg to 160 mg of the same compound.

Career Highlights

Throughout his career, MacLean has worked with prominent companies in the pharmaceutical industry, including Takeda Pharmaceutical Company Limited and Myovant Sciences GmbH. His expertise in drug development and innovative treatment methods has positioned him as a key figure in the fight against prostate cancer.

Collaborations

MacLean has collaborated with several professionals in his field, including Vijaykumar Reddy Rajasekhar and Brendan Mark Johnson. These partnerships have contributed to the advancement of his research and the successful development of his patented methods.

Conclusion

David B MacLean's contributions to prostate cancer treatment through his innovative patents highlight his dedication to improving patient outcomes. His work continues to influence the medical community and offers hope for those affected by this disease.